Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H24O4 |
Molecular Weight | 304.3808 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@]12CC[C@H]3[C@@H](CCC4=CC(O)=CC=C34)[C@@H]1[C@@H](O)[C@@H](O)[C@@H]2O
InChI
InChIKey=AJIPIJNNOJSSQC-NYLIRDPKSA-N
InChI=1S/C18H24O4/c1-18-7-6-12-11-5-3-10(19)8-9(11)2-4-13(12)14(18)15(20)16(21)17(18)22/h3,5,8,12-17,19-22H,2,4,6-7H2,1H3/t12-,13-,14-,15-,16-,17+,18+/m1/s1
Molecular Formula | C18H24O4 |
Molecular Weight | 304.3808 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Estetrol is the natural human fetal selective estrogen receptor modulator. It is synthesized exclusively by the human fetal liver during pregnancy. Estetrol has a moderate affinity for human estrogen A receptor (ERa) and estrogen B receptor (ERb). Estetrol may be suitable as a potential drug for human use in applications such as hormone replacement therapy (vaginal atrophy, hot flushes), contraception and osteoporosis. The most common drug-related adverse events were lower abdominal pain, nausea, headache, dysmenorrhoea, breast enlargement and acne. Estetrol had been in clinical trials for the treatment of breast and prostate cancers.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL206 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18464023 |
4.9 nM [Ki] | ||
Target ID: CHEMBL242 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18464023 |
19.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
17.9 ng/mL |
14.2 mg single, oral dose: 14.2 mg route of administration: Oral experiment type: SINGLE co-administered: DROSPIRENONE |
ESTETROL plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
56.59 ng/mL EXPERIMENT https://doi.org/10.3390/ijms24119718 |
45 mg single, oral dose: 45 mg route of administration: Oral experiment type: SINGLE co-administered: |
ESTETROL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
8.01 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28267365 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
ESTETROL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
87.3 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28267365 |
40 mg 1 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ESTETROL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
59.1 ng × h/mL |
14.2 mg single, oral dose: 14.2 mg route of administration: Oral experiment type: SINGLE co-administered: DROSPIRENONE |
ESTETROL plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
321.05 ng × h/mL EXPERIMENT https://doi.org/10.3390/ijms24119718 |
45 mg single, oral dose: 45 mg route of administration: Oral experiment type: SINGLE co-administered: |
ESTETROL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
194.2 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28267365 |
40 mg 1 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ESTETROL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
27 h |
14.2 mg single, oral dose: 14.2 mg route of administration: Oral experiment type: SINGLE co-administered: DROSPIRENONE |
ESTETROL plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
26.64 h EXPERIMENT https://doi.org/10.3390/ijms24119718 |
45 mg single, oral dose: 45 mg route of administration: Oral experiment type: SINGLE co-administered: |
ESTETROL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
52% |
14.2 mg single, oral dose: 14.2 mg route of administration: Oral experiment type: SINGLE co-administered: DROSPIRENONE |
ESTETROL plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
100 mg single, oral Highest studied dose |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
|
15 mg 1 times / day multiple, oral Minumum effective dose Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
Disc. AE: uterine bleedin... AEs leading to discontinuation/dose reduction: uterine bleedin (grade 3, 2%) Sources: |
60 mg 1 times / day multiple, oral Studied dose Dose: 60 mg, 1 times / day Route: oral Route: multiple Dose: 60 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
uterine bleedin | grade 3, 2% Disc. AE |
15 mg 1 times / day multiple, oral Minumum effective dose Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02817828
Curator's Comment: in combination with 3 mg drospirenone tablets
15 mg administered once daily for 13 consecutive cycles following a 24/4-day regimen.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18464023
Binding of Estetrol at the glucocorticoid, progesterone and
testosterone receptors was only 11–15% at a concentration of 10 uM/l. Estetrol at a high concentration of 10 uM/l did not inhibit the major cytochrome P450 enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 07:55:24 GMT 2025
by
admin
on
Wed Apr 02 07:55:24 GMT 2025
|
Record UNII |
ENB39R14VF
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
678119
Created by
admin on Wed Apr 02 07:55:24 GMT 2025 , Edited by admin on Wed Apr 02 07:55:24 GMT 2025
|
||
|
EU-Orphan Drug |
EU/3/17/1865
Created by
admin on Wed Apr 02 07:55:24 GMT 2025 , Edited by admin on Wed Apr 02 07:55:24 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
ESTETROL
Created by
admin on Wed Apr 02 07:55:24 GMT 2025 , Edited by admin on Wed Apr 02 07:55:24 GMT 2025
|
PRIMARY | |||
|
10439
Created by
admin on Wed Apr 02 07:55:24 GMT 2025 , Edited by admin on Wed Apr 02 07:55:24 GMT 2025
|
PRIMARY | |||
|
DTXSID50164888
Created by
admin on Wed Apr 02 07:55:24 GMT 2025 , Edited by admin on Wed Apr 02 07:55:24 GMT 2025
|
PRIMARY | |||
|
2539031
Created by
admin on Wed Apr 02 07:55:24 GMT 2025 , Edited by admin on Wed Apr 02 07:55:24 GMT 2025
|
PRIMARY | |||
|
FG-207
Created by
admin on Wed Apr 02 07:55:24 GMT 2025 , Edited by admin on Wed Apr 02 07:55:24 GMT 2025
|
PRIMARY | |||
|
C68928
Created by
admin on Wed Apr 02 07:55:24 GMT 2025 , Edited by admin on Wed Apr 02 07:55:24 GMT 2025
|
PRIMARY | |||
|
ENB39R14VF
Created by
admin on Wed Apr 02 07:55:24 GMT 2025 , Edited by admin on Wed Apr 02 07:55:24 GMT 2025
|
PRIMARY | |||
|
ENB39R14VF
Created by
admin on Wed Apr 02 07:55:24 GMT 2025 , Edited by admin on Wed Apr 02 07:55:24 GMT 2025
|
PRIMARY | |||
|
Estetrol (medication)
Created by
admin on Wed Apr 02 07:55:24 GMT 2025 , Edited by admin on Wed Apr 02 07:55:24 GMT 2025
|
PRIMARY | |||
|
27125
Created by
admin on Wed Apr 02 07:55:24 GMT 2025 , Edited by admin on Wed Apr 02 07:55:24 GMT 2025
|
PRIMARY | |||
|
DB12235
Created by
admin on Wed Apr 02 07:55:24 GMT 2025 , Edited by admin on Wed Apr 02 07:55:24 GMT 2025
|
PRIMARY | |||
|
142773
Created by
admin on Wed Apr 02 07:55:24 GMT 2025 , Edited by admin on Wed Apr 02 07:55:24 GMT 2025
|
PRIMARY | |||
|
15183-37-6
Created by
admin on Wed Apr 02 07:55:24 GMT 2025 , Edited by admin on Wed Apr 02 07:55:24 GMT 2025
|
PRIMARY | |||
|
100000172329
Created by
admin on Wed Apr 02 07:55:24 GMT 2025 , Edited by admin on Wed Apr 02 07:55:24 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST |
Ki
|
||
|
SOLVATE->ANHYDROUS |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> AGONIST |
Ki
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|